Summary of AVITA Medical, Inc. Q4 and Full Year 2025 Earnings Call

1Key Financial Results and Metrics

Q4 Revenue: $17.6 million, down from $18.4 million in Q4 2024.

Full Year Revenue: Approximately $71.6 million, representing an 11% increase over 2024.

Gross Margin: Q4 gross margin was 81.2%, down from 87.6% in the prior year; full year gross margin was 82.1%, down from 85.8%.

Operating Expenses: Q4 operating expenses totaled $24.7 million, a 5% decrease year-over-year, with a notable reduction in sales and marketing expenses.

Cash Position: Ended Q4 with $18.2 million in cash and marketable securities, with a significant reduction in net cash used, declining to $5.1 million in Q4 from $10.1 million in Q2.

2Strategic Updates and Business Highlights

Focused on disciplined execution, refining commercial strategies, and enhancing growth positioning for 2026.

Resolved reimbursement uncertainties for RECELL, with 6 of 7 Medicare administrative contractors (MACs) publishing payment rates, which is expected to normalize utilization.

Emphasis on increasing adoption and repeat use of products (RECELL, Cohealyx, and PermeaDerm) within existing accounts, primarily burn and trauma centers.

Clinical studies for Cohealyx and PermeaDerm are progressing, with data expected in 2026 to support their market adoption.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected to be between $80 million and $85 million, reflecting growth of 12% to 19% over 2025.

Anticipated growth driven by normalization of RECELL utilization and expanded use of Cohealyx and PermeaDerm within existing accounts.

The company aims for consistent quarter-by-quarter execution rather than relying on one-time events for growth.

4Bad News, Challenges, or Points of Concern

Q4 revenue decline compared to the previous year raises concerns about immediate growth momentum.

Gross margin pressures due to product mix and inventory reserves, although still above 80%.

Dependency on the resolution of the seventh MAC's reimbursement rate, with ongoing engagement but no timeline provided for resolution.

Potential risks associated with the adoption rates of Cohealyx and PermeaDerm, which are still in early stages of market penetration.

5Notable Q&A Insights

Management clarified that the $15.4 million revenue covenant is not indicative of guidance but rather provides flexibility and reduces covenant risk.

There is confidence in gradual growth from Q4 into Q1 2026, with expectations for continued improvement in utilization.

Discussions highlighted the importance of clinical champions in driving the adoption of new products and the ongoing administrative processes involved in MAC reviews.

Management expressed optimism about the integration of Cohealyx and PermeaDerm into existing accounts, which could further drive RECELL utilization. Overall, AVITA Medical is positioning itself for a more stable and predictable growth trajectory in 2026, focusing on execution and operational discipline while navigating challenges related to reimbursement and product adoption.